key: cord-0577082-t3eyywal authors: Gao, Xin; Li, Jianwei; Li, Dianjie title: Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness date: 2022-04-05 journal: nan DOI: nan sha: 1a0f80a9510f6ba280a782bd6470ffbb2df2abc1 doc_id: 577082 cord_uid: t3eyywal COVID-19 vaccines have proven to be effective against SARS-CoV-2 infection. However, the dynamics of vaccine-induced immunological memory development and neutralizing antibodies generation are not fully understood, limiting vaccine development and vaccination regimen determination. Herein, we constructed a mathematical model to characterize the vaccine-induced immune response based on fitting the viral infection and vaccination datasets. With the example of CoronaVac, we revealed the association between vaccine-induced immunological memory development and neutralizing antibody levels. The establishment of the intact immunological memory requires more than 6 months after the first and second doses, after that a booster shot can induce high levels neutralizing antibodies. By introducing the maximum viral load and recovery time after viral infection, we quantitatively studied the protective effect of vaccines against viral infection. Accordingly, we optimized the vaccination regimen, including dose and vaccination timing, and predicted the effect of the fourth dose. Last, by combining the viral transmission model, we showed the suppression of virus transmission by vaccination, which may be instructive for the development of public health policies. SARS-COV-2 and its variant of concerns (VOCs) are highly contagious pathogens (1), cumulatively resulting in over 340 million infections and more than 5.5 million deaths worldwide by the end of February 2022. Vaccination, as an effective and promising way against SARS-COV-2, reduces the spread of COVID-19 and risk of severe illness significantly (2) . Clinical studies have demonstrated the safety and efficacy of the vaccines, including inactivated vaccines (such as CoronaVac and Sinopharm), mRNA vaccines (such as Moderna and Pfizer-BioNTech) and other types of COVID-19 vaccines (3) (4) (5) . Therefore, vaccines and booster shots have recognized as an important measure for the prevention of COVID-19 (6) . However, the dynamic mechanism underlying the protection of vaccines against SARS-COV-2 infection has not been fully elucidated. Recently, dynamics models have been widely used to study the transmission and infection processes of COVID-19 (7) (8) (9) (10) , helping us to quantitatively analyze the spread of viruses and to establish corresponding public safety policies. In the early stages of COVID-19 epidemic, a study pointed out that COVID-19 would cause over 500,000 deaths in the UK if without government intervention (8) , which provided the rationale for the need for an epidemic prevention policy in the UK. In addition, another study (7) demonstrated that Wuhan closure reduced the number of infections by 96% using SAPHIRE dynamic model, a model combined both infectious properties of COVID-19 and the population mobility. In addition to studying populationlevel dynamical models, models of within-host viral infection can quantitatively simulate the processes of viral proliferation and clearance, giving a basis for evaluating the medication strategies (10) . Therefore, dynamics modeling is a promising approach to deepen our understanding of the host immune response induced by vaccines. Currently, more than 30 approved vaccines are in clinical use and 178 vaccine candidates are in development worldwide (covid19.trackvaccines.org). CoronaVac, as an example, is an inactivated vaccine against COVID-19, containing inactivated SARS-COV-2 virus. The previous study has proved that the first and second doses of CoronaVac vaccination were well tolerated and had moderate immunogenicity in individuals aged 18-59 years (3) . Dose comparisons revealed that the 6 ug dose of CoronaVac generated slightly higher geometric mean titers (GMTs) of neutralizing antibodies than the 3 ug dose of CoronaVac, and the incidence of adverse reactions were close in 3 ug and 6 ug trials (11) . Further study found that despite a sharp decline in GMTs 8 months after the second dose, the booster shot increases GMTs by tens of times (11) . Notably, booster shots inoculated 2 months after the second injection resulted in much lower GMTs than the group that inoculated booster shots 8 months later (11) . These results show that the formation of intact antibody-associated immunological memory may cost several months in recipients after vaccination (12) . Through dynamical modeling, we can explain this phenomenon and predict GMTs for a possible fourth shot. Here, based on viral load (VL) and GMTs data after vaccination, we developed a simplified mathematical model to recapitulate the dynamics of immunogenicity and immunological memory after vaccination with CoronaVac. To evaluate the vaccine-induced adaptive immune response and immunological memory, we constructed a simplified within-host immune network mainly focusing on humoral immunity. This network consisted of three Once memory B cells encounters similar antigen, they will differentiate into effector module, producing a rapid response to specific antigens. This process is be described by the self-proliferation of and the conversion to in response to antigenic stimulation. Based on the network in Fig. 1A , we build a 3-variable ordinary differential equations model to describe the dynamic process of immune response against SARS-CoV-2 virus as follows: We first investigated the dynamics of viral infection. We adopted the NBA dataset, from the study of Ke et al. and Kissler et al (10, 14) . The NBA dataset contains VL data from early stage of infections, and early stage data allow us to fit the proliferation process of virus more accurately. We used our model to fit the NBA dataset (see Methods). The results (Fig. 1B) shows that the average viral proliferation rate for the nine individuals is 3.3 day -1 (SD: 1.6); the viral clearance rate is 0.018 AU -1 day -1 (SD: 0.00065); the proliferation rate of the effector module is 3.6 day -1 (SD: 3.4). We set the proliferation rate of the effector module under antigenic stimulation to be 1 AU -1 day -1 . We assumed carrying capacity of was to ensure that the virus growth period was shorter than the virus clearance period. 1 is the Hill coefficient for proliferation induced by antigens, which we estimated to be 10 4 /mL (We discuss the value of 1 in Supplementary information 1). The mean recovery time for patients with mild viral infections is around 15 days (95% CI, 13-18) (16) , which is close to our simulations (13.9 days, Fig. 1C ). In addition to the dynamics of the SARS-CoV-2 infection, we also investigated how the virus or vaccine activates immune memory infection. Immune memory, which provides long-term protection against viruses, consists mainly of memory CD4+ T cells, memory CD8+ T cells, antibodies and memory B cells (17, 18) , and demonstrate various dynamics (19) . We focus on the formation of humoral immune memory, especially memory B cells. Dan et al. found that SARS-CoV-2 spike specific memory B cells increase gradually after infection, peaking at 8 months, and will persist for a long time (15) . We introduced the data of memory B cells and fitted it by our model (Fig. 1D ). We assumed that the environmental carrying capacity of memory module to be 100. The fitted proliferation rate of memory module is 0.020 day -1 (SD: Based on the fitted parameters of viral clearance and immune memory formation, we further investigated the vaccine-induced immune response. Considering that inactivated SARS-CoV-2 in CoronaVac is incapable of proliferation, we modify virus proliferation rate to zero in equation ⑴. We introduced three doses vaccination data from Zeng et al. (11) , which contains GMTs measured after 3 ug and 6 ug doses of CoronaVac under four vaccination regimens respectively ( Fig. 2A-B) . To simulate GMTs with our model, we assumed that the effector module is proportional to the values of GMT and satisfies = 2 × (rapid equilibrium assumption, Methods), and we fitted the natural apoptosis rate of effector module q by 0.018 day -1 (SD: 0.0016) based on the degradation of GMTs (11) . We used our model to fit the vaccination data for all regimens simultaneously and best fit result show that the equivalent VL in CoronaVac (eVL) is 117 copies/(mL*ug) (SD: 1.6), the differentiation rate of into , , is 0.077 day -1 mL (SD: 0.0020), the environmental carrying capacity of , , is 250 A.U. (we discuss the influence of in Supplementary Information 1) , and 2 is 0.42 (SD: 0.0029). Based on fitting the model to the vaccine data, we could demonstrate the evolution of and under different vaccination regimens ( Fig. 2A-B) . The We also found that 6 ug CoronaVac can produce higher level GMTs than 3 ug CoronaVac after both the first and second doses or the third dose and no evidence shows higher adverse effects of the 6 ug CoronaVac than 3 ug. The effect of vaccine dose on GMTs will be discussed in a subsequent section. The results show that the MVL for reinfection is low after recovery from the first infection, indicating that individual is well protected against reinfection. Moreover, the MVL and RT were similar between those who received three complete doses of vaccine and those who were infected with the virus six months later. In a previous three-dose CoronaVac study (11) We demonstrated the probability of transmission after infection in unvaccinated population, vaccinated with 2 doses population and vaccinated with 3 doses population (Fig. 5B) . We find that 2-dose vaccination of mutantspecific vaccine reduced the probability of transmission by 77% (from 0.066 to 0.015), while a full 3-dose vaccination reduced the probability of transmission by 88% (from 0.066 to 0.008). Besides the probability of transmission, 0 , the basic reproduction number, is a better-known indicator to measure viral transmission in a population. Social policy, such as wearing face masks, can effectively reduce the value of 0 . Similarly, vaccinating a population of mutant-specific vaccine can also reduce 0 (Fig. 5C ). The reproduction number for individual i, 0, , can be written as: where c is the contact numbers per day and is the probability of transmission for individual i. When 0 of a population is less than 1, the illness will gradually stop spreading. Thus, without considering the differences in the timing of vaccination in a population, we can calculate the maximally allowed contact numbers per day after vaccination for 0 < 1 (Fig. 5D) . Considering the average contact number 0 in the EU is 13.4 (24) , strict social policies are necessary until two months after two doses of vaccines to reduce and make 0 < 1 in principle. In Then, we explored the optimal vaccine strategy and the impact of vaccines on viral transmission by power-law model (23) In this model, we performed the fitting of the parameters in three steps to avoid crosstalk of parameters. First, considering that immune memory takes mouths to establish, whose time scale is much larger than the infection, we separated memory module when fitting initial infection and the model degenerated into We obtained the estimated value of , , and by fitting the initial infection VL data from NBA dataset (10, 14) . Second, when fitting the post-infection memory B-cell generation process, we neglected the transition from the memory module to the effector module considering the absence of reactivation of antigen. Then, the model becomes Similarly, we obtained the estimated of 1 , , and by fitting. Third, based on the parameters that obtained above, we fitted the vaccine data using the complete model. This fitting process is performed by fitting antibody levels for all vaccination regimens simultaneously, that is, for a certain set of parameters, the effector module dynamics under different vaccination regimens is calculated simultaneously and then compare with the data. This fitting process helped us to estimate , 2 , and . We adopted the least squares method for the above fitting, using the leastsq package from scipy. The standard deviation of each parameter was estimated as the arithmetic square root of the diagonal elements of the covariance matrix of the fitted results. To better illustrate the impact of parameters on simulation results, we used SALib package for parametric sensitivity analysis. First, we defined the impact (Err) as the deviation from the original trajectory in the space of , , and : To describe the association between VL and probability of transmission (p), we introduced the study of Ke et al. (10) and calculated the probability of transmission for a typical contact at time t by the saturation model as where V is the measured VL. The value of , and ℎ are 0.2, 8.9*10 6 copies/mL and 0.51 respectively (10) . Besides the saturation model, the probability of transmission can also be calculated by the power-law function as where =2.4*10 -5 and ℎ=0.53 (10) . We compared the probability of transmission after vaccination calculated by the saturation model and the power-law model in Supplementary Information 3. A Novel Coronavirus from Patients with Pneumonia in China COVID-19 vaccines and decreased transmission of SARS-CoV-2 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Prevention of host-to-host transmission by SARS-CoV-2 vaccines COVID-vaccine booster shot shows promise in Israeli study Reconstruction of the full transmission dynamics of COVID-19 in Wuhan Special report: The simulations driving the worlds response to COVID-19 Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons In vivo kinetics of SARS-CoV-2 infection and its relationship with a persons infectiousness Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. The Lancet Infectious Diseases mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern Homeostatic proliferation of B cells Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Remdesivir for the Treatment of Covid-19 -Final Report Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals COVID-19 and the Path to Immunity Cross-reactive memory T cells and herd immunity to SARS-CoV-2 Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy. Vaccines (Basel) 9 Mechanisms of SARS-CoV-2 Transmission and Pathogenesis Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals Estimating infectiousness throughout SARS-CoV-2 infection course Social contacts and mixing patterns relevant to the spread of infectious diseases Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants We thank Ziheng Zhao and Fangting Li for useful discussion. The authors declare that they have no competing interests. There are no original data in this work. Previously published data were used for this study (10, 11, 14, 15) .